You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,018,638

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,018,638

Title:	Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
Abstract:	The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
Inventor(s):	Albitar; Maher (Sugar Land, TX), Keating; Michael J. (Houston, TX), Manshouri; Taghi (Houston, TX)
Assignee:	Board of Regents, The University of Texas System (Austin, TX)
Application Number:	15/606,877
Patent Claims:	1. A method for determining a dosage of a therapeutic anti-CD20 antibody for treating B cell hyperproliferative disease, the method comprising testing a sample from a human to measure the level of soluble CD20, and determining the dosage of the therapeutic anti-CD20 antibody according to the level of soluble CD20. 2. The method of claim 1, wherein said sample is selected from the group consisting of plasma, serum, and cell lysate. 3. The method of claim 1, wherein said therapeutic anti-CD20 antibody is Rituximab. 4. The method of claim 1, wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocyte leukemia, multiple myeloma, hairy cell leukemia, prolymphocytic leukemia, or lymphoma. 5. The method of claim 4, wherein said B-cell hyperproliferative disease is chronic lymphocytic leukemia. 6. The method of claim 1, further comprising administering said therapeutic anti-CD20 antibody to said human. 7. The method of claim 3, further comprising administering said Rituximab to said human.

Details for Patent 10,018,638

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2021-09-20
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2021-09-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.